aromatase inhibitor Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 1 (1)

Interventional (1)

SOLTI Breast Cancer Research Group (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadbreast cancer

I am/have/hadmetastasis

I am/have/hadabsolute neutrophil count

I am/have/hadgilbert's syndrome

I am/have/hadplatelet count

I am/have/hadadjuvant therapy

I am/have/hadejection fraction

I am/have/hadprogressive disease

I am/have/hadffpe

I am/have/hadinvasive breast cancer

I am/have/hadher2 positive breast carcinoma

I am/have/hadbreast adenocarcinoma

I am/have/hadstage iv breast cancer

I am/have/hadcancer

I am/have/hadhcg pregnancy test

I am/have/hadserum bilirubin level

I am/have/hadmetastatic adenocarcinoma

I am/have/hadpik3ca

I am/have/hadadenocarcinoma

I am/have/hadneutrophil count

added new label for I am/have/had

more

I am looking for

I am looking foradjuvant

I am looking fortrastuzumab

I am looking forglycosylated hemoglobin

I am looking forpertuzumab

I am looking fortaxane

I am looking forpik3ca

I am looking forimmunological adjuvant

I am looking foripatasertib

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients

This is an open label, single arm, multicenter, phase Ib study to evaluate the safety and clinical activity of the combination of ipatasertib, trastuzumab and pertuzumab in patients with unresectable locally advanced or metastatic HER2-positive breast cancer with tumors harboring PIK3CA mutations, candidates to receive maintenance HP after first line …

metastasis

adjuvant

invasive breast cancer

her2 positive breast carcinoma

breast adenocarcinoma

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2025 All rights reserved.